Precigen, Inc. PGEN
4.65 USD +0.13 (+2.77%)
Nov 11, 2026, 11:35 AM EST
4.50 Day range 4.70
3.04 52-week range 8.98
- YTD
- +11.12%
- 1 year
- +17.30%
News
zacks.com What Makes Precigen (PGEN) a New Buy Stock Precigen (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com PGEN Q3 Earnings Call Highlights Launch Momentum and Competition Precigen's PAPZIMEOS launch gains traction with 37% sequential revenue growth, positive cash flow and expanding patient access as competition looms.
benzinga.com Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12 Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $11 to $12.
seekingalpha.com Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
marketbeat.com What Precigen (PGEN) Said on Its Q3 Earnings Call Precigen NASDAQ: PGEN reported $72.9 million in third-quarter 2026 sales of PAPZIMEOS, its treatment for adults with recurrent respiratory papillomatosis, as the company posted a second consecutive…
zacks.com Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates Precigen, Inc. (PGEN) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.11 per share a year ago.
benzinga.com Precigen Q3 2026 Earnings Call Transcript Precigen (NASDAQ:PGEN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com Precigen Q3 EPS $0.08 Beats $0.07 Estimate, Sales $74.148M Beat $71.558M Estimate Precigen (NASDAQ:PGEN) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.07 by 14.29 percent. This is a 107.55 percent increase over losses of $(1.06) per…
prnewswire.com Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance PAPZIMEOS ® net revenue rose 37% quarter-over-quarter to $72.9 million in the third quarter of 2026 bringing launch-to-date net product revenue to $151 million, underscoring sustained commercial…
benzinga.com Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Kosmos Energy plunged 13.6% after missing Q3 earnings and sales estimates; other stocks also fell in premarket trading.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
benzinga.com Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures fell; Constellation Brands dropped 5.1% despite beating estimates, while biotech, mining and other stocks declined premarket.
benzinga.com This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.
benzinga.com B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12 B. Riley Securities analyst Yuan Zhi initiates coverage on Precigen (NASDAQ:PGEN) with a Buy rating and announces Price Target of $12.
benzinga.com Toast To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP Morgan downgraded Ball, Needham raised Hinge Health.- benzinga.com HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $14 to $18.
benzinga.com Why Arista Networks Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket Arista Networks Inc (ANET) reported strong Q2 results, with revenue of $3.04B, up 37.7% YoY. Shares rose 13% in pre-market trading.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
benzinga.com HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $14 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $14 price target.
benzinga.com HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $14 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $11 to $14.
benzinga.com Precigen Says FDA Grants Orphan Drug Exclusivity For PAPZIMEOS For Treatment Of Adults With Recurrent Respiratory Papillomatosis FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosisSeven-year period of PAPZIMEOS market exclusivity is effective through August 14,…
benzinga.com Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11 Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $9 to $11.- benzinga.com HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $10 to $11.
benzinga.com Why Cisco Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Cisco Inc (NASDAQ: CSCO) beat expectations and raised guidance with $15.84B revenue and $1.06 EPS. Shares jumped 17.3% in pre-market trading.
benzinga.com Transcript: Precigen Q1 2026 Earnings Conference Call - benzinga.com Precigen Q1 EPS $(0.02), Inline, Sales $23.252M Beat $20.800M Estimate Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 88.89 percent increase over losses of $(0.18) per share from the same period…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Precigen Sees Strong Early Demand for New Immunotherapy Since Launch, CMS Reimbursement Code Boosts Access as Sales Expected to Top $18M Precigen Inc. (NASDAQ:PGEN), a commercial-stage biopharmaceutical company developing precision medicines to improve the quality of life for people suffering from recurrent respiratory papillomatosis…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Crude Oil Gains 4%; Commercial Metals Posts Mixed Q2 Results The U.S. trade deficit in goods shrank to $87.3 billion in February from $88.6 billion in January, while exports gained 8.7% to $142.0 billion. U.S. stocks traded lower, with the Nasdaq down 1%.…
benzinga.com These Analysts Boost Their Forecasts On Precigen Following Q4 Results Precigen, Inc. (NASDAQ:PGEN) reported mixed Q4 results, with a loss of 1 cent per share beating estimates but sales of $4.565 million falling short.
benzinga.com Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.- benzinga.com Citizens Maintains Market Outperform on Precigen, Raises Price Target to $9 Citizens analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target from $8 to $9.
benzinga.com HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $10 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $9 to $10.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Navan Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Shares of Navan Inc (NASDAQ: NAVN) spiked in pre-market trading on better-than-expected Q4 results. Gainers include EEIQ, FCHL, OLPX, SLND, PGEN, EDHL, NFGC, NEXT, and VG. Losers include MGN, CBUS,…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Precigen Q4 EPS $(0.01) Beats $(0.08) Estimate, Sales $4.565M Miss $8.286M Estimate Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.95 percent. This is a 83.33 percent increase over losses of $(0.06)…
- benzinga.com Earnings Scheduled For March 25, 2026
- benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Precigen Provides Update On Therapy For Recurrent Respiratory Papillomatosis, To Present Data At J.P. Morgan Healthcare Conference Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today provided an…
benzinga.com Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
benzinga.com DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $9 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price target from $8.5 to $9.
- benzinga.com Precigen Q3 EPS $(1.06) Misses $(0.10) Estimate, Sales $2.922M Beat $500.000K Estimate Precigen (NASDAQ:PGEN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.10) by 1015.79 percent. This is a 1077.78 percent decrease over losses of…
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com Exploring Precigen's Earnings Expectations